Talk:Irene Ghobrial

☆ Save On Wikipedia ↗

Problems

None of the new editors have sought the talk page. I note that there's more sourcing available for the scandal--like here, for instance, and that's reliable. It also made headlines in the tabloids and the right-wing blogs, but that's not worth citing here. User:Truthinscience247 says "it's all been handled" (but there is no evidence of it), User:Ighobrial said nothing at all--both of you, this, this talk page, is where things will have to be hashed out. Drmies (talk) 00:39, 25 April 2024 (UTC)

COI tag (May 2026)

The majority of the text of the page has been added by an account who has made no edits except to add promotionally-tinged content to this page AntiDionysius (talk) 16:54, 13 May 2026 (UTC)

Requested edit to “Research and career” section (COI)

I am requesting an edit to the “Research and career” section of this article. I have a conflict of interest because I am posting suggested text on behalf of the subject. I am therefore not editing the article directly and am submitting the proposed content below for independent review.

Proposed replacement text for “Research and career”

Ghobrial’s research focuses on the biology, early detection, and clinical management of precursor plasma‑cell disorders, including monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Her laboratory investigates mechanisms of disease progression from precursor states to multiple myeloma (MM), with an emphasis on identifying biomarkers, developing risk‑stratification models, and evaluating early‑intervention strategies.

Ghobrial established the Center for Early Detection and Interception of Blood Cancers, which conducts prospective monitoring of individuals with precursor conditions such as MGUS, early myelodysplastic syndromes (MDS), and early chronic lymphocytic leukemia (CLL). The program integrates clinical, genomic, and immune profiling to study clonal evolution and progression.

Her group has contributed to the development of genomic and molecular predictors of progression from MGUS and SMM to MM. This work includes identifying genomic alterations associated with progression,[1] generating whole‑genome sequencing datasets to support genomic risk modelling,[2] and developing the PANGEA model, a time‑varying biomarker approach for dynamic risk stratification in SMM.[3]

Ghobrial’s laboratory has also developed minimally invasive approaches for disease monitoring. Her group demonstrated that genomic profiling of circulating tumour cells (CTCs) captures clonal heterogeneity comparable to bone marrow biopsies, contributing to the development of MinimuMM‑seq, a whole‑genome sequencing method for CTCs,[4] and SWIFT‑seq, a single‑cell transcriptional profiling approach for identifying programs associated with progression.[5] This work has been covered in independent media, including *STAT News*.[6]

Using single‑cell sequencing, her group reported that immune dysregulation begins at the precursor stage and evolves during progression,[7] and identified immune biomarkers associated with response to immunotherapy in high‑risk SMM.[8]

Ghobrial has led clinical trials evaluating early‑intervention strategies in SMM, including studies of bispecific antibodies,[9] and a phase 2 trial of CAR‑T cell therapy (CAR‑PRISM) in high‑risk SMM, published in *Nature Medicine* in 2026.[10][11][12] She has also served on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee panels for therapies including cilta‑cel (Carvykti)[13] and daratumumab for high‑risk SMM.[14]

Her awards include the Robert A. Kyle Award (2010), election to the American Society for Clinical Investigation (2011), the Dana‑Farber Mentor of the Year Award (2014), the International Myeloma Society’s Ken Anderson Basic and Translational Research Award (2017), and a Stand Up To Cancer grant to co‑lead the Multiple Myeloma Dream Team (2018).[15] She received the American Society of Hematology’s William Dameshek Prize in 2022,[16] the Francesca Cassinelli Senior Researcher Award in 2025,[17] and was named a Giant of Cancer Care in the Myeloma category in 2026.[18]

In 2024, *The Harvard Crimson* reported allegations of research misconduct involving several Dana‑Farber Cancer Institute scientists, including Ghobrial.[19] Corrections were issued for several publications, but none of her papers were retracted.[20] In 2025, Dana‑Farber agreed to a $15 million settlement with the U.S. Department of Justice related to research‑grant practices; Ghobrial was not a party to the settlement.[21][22]

Thank you for reviewing this request. BM101345 (talk) 16:06, 15 May 2026 (UTC)

  1. "Genomic Score May Predict Progression From Precursor Condition to Active Multiple Myeloma". The ASCO Post. Retrieved 2026-05-13.
  2. Chabrun, Floris; et al. (2026-03-24). "Enhanced dynamic risk stratification of smoldering multiple myeloma". Nature Medicine: 1–9. doi:10.1038/s41591-026-04304-x. ISSN 1546-170X.
  3. Chabrun, Floris; et al. (2026-03-24). "Enhanced dynamic risk stratification of smoldering multiple myeloma". Nature Medicine: 1–9. doi:10.1038/s41591-026-04304-x. ISSN 1546-170X.
  4. Lancaster, Charlene. "Monitoring Multiple Myeloma Progression through Sequencing". The Scientist. Retrieved 2026-05-13.
  5. "Novel Single-Cell Sequencing Blood Test for Multiple Myeloma". The ASCO Post. Retrieved 2026-05-13.
  6. "Groundbreaking blood test for multiple myeloma". STAT. Retrieved 2026-05-13.
  7. Zavidij, Oksana; et al. (2020-05). "Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma". Nature Cancer. 1 (5): 493–506. doi:10.1038/s43018-020-0053-3. PMC 7785110. PMID 33409501. {{cite journal}}: Check date values in: |date= (help)
  8. Sklavenitis-Pistofidis, Romanos; et al. (2022-11-14). "Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma". Cancer Cell. 40 (11): 1358–1373.e8. doi:10.1016/j.ccell.2022.10.017. PMC 10019228. PMID 36379208.
  9. "Smoldering Multiple Myeloma - A Unique New Approach". Dana-Farber Cancer Institute. Retrieved 2026-05-13.
  10. Nadeem, Omar; et al. (2026-04-20). "Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial". Nature Medicine: 1–10. doi:10.1038/s41591-026-04365-y. ISSN 1546-170X.
  11. Chen, Angus (2026-04-20). "In early trial, CAR-T results raise hope of preventing multiple myeloma in high-risk patients". STAT.
  12. "CAR-PRISM trial reports promising results in high-risk smoldering multiple myeloma". News-Medical. 2026-04-21. Retrieved 2026-05-13.
  13. Sava, Jordyn (2026-05-13). "FDA's ODAC Finds Cilta-Cel Favorable in R/R Multiple Myeloma". Targeted Oncology.
  14. "Meeting of the Oncologic Drugs Advisory Committee - May 20-21, 2025". FDA. 2025-07-17. Retrieved 2026-05-13.
  15. Chen, Angus (2022-04-21). "Multiple myeloma is usually detected late. Some researchers think a precursor could help catch it early". STAT.
  16. "Dana-Farber professor receives William Dameshek Prize for multiple myeloma research". Healio. Retrieved 2024-06-11.
  17. "Cassinelli Award 2025: Official Announcement of the Winners". Fondazione di Piacenza e Vigevano. 2026-03-06. Retrieved 2026-05-13.
  18. "Giants of Cancer Care® announces the 14th annual class of inductees". MJH Life Sciences. 2026-05-08. Retrieved 2026-05-13.
  19. "Dana-Farber Cancer Institute Researchers Accused of Manipulating Data". The Harvard Crimson. Retrieved 2024-06-11.
  20. Sahin, I.; et al. (2024-04-23). "Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma". Blood Advances. 8 (8): 1958. doi:10.1182/bloodadvances.2024013092. PMC 11033686. PMID 38619855.
  21. "Dana-Farber Cancer Institute Agrees to Pay $15M to Settle Fraud Allegations Related to Scientific Research Grants". U.S. Department of Justice. 2025-12-16. Retrieved 2026-05-13.
  22. Wosen, Jonathan (2025-12-16). "Dana-Farber to pay $15 million to settle Justice Department lawsuit over manipulated data". STAT.